Jupiter Neurosciences (JUNS): Jotrol’s Bioavailability Breakthrough and the Key Parkinson’s Phase 2A Readout

In this episode, Christer Rosen, Founder and CEO of Jupiter Neurosciences (Nasdaq: JUNS), and President & COO Alison Silva join Water Tower Research’s Tim Gerdeman and Healthcare Analyst Robert Sassoon to discuss Jotrol, the company’s proprietary micellar formulation of resveratrol engineered to overcome long‑standing bioavailability and tolerability limitations. Jotrol has demonstrated a ninefold increase in resveratrol bioavailability, enabling therapeutic exposure without the high‑dose GI side effects that have historically constrained the molecule’s therapeutic potential.The team highlights progress on the active Phase 2A Parkinson’s trial enrolling at Georgetown University, designed to evaluate safety, PK, and neuroinflammatory biomarkers, with data expected in early 2027. Management also outlines Jupiter’s dual‑engine strategy spanning clinical development, a consumer longevity brand, and new licensing initiatives including ALA‑002.